Yellow Fever - Pipeline Review, H2 2017

  • ID: 4418936
  • Report
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • Bavarian Nordic A/S
  • Ennaid Therapeutics LLC
  • Fab'entech SA
  • iBio Inc
  • Johnson & Johnson
  • MORE
Yellow Fever - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Yellow Fever - Pipeline Review, H2 2017, provides an overview of the Yellow Fever (Infectious Disease) pipeline landscape.

Yellow fever is an acute systemic illness (hemorrhagic fever) caused by the Flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There is no specific treatment for yellow fever but can be treated to relieve the symptoms.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Yellow Fever - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Yellow Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Yellow Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 8 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Yellow Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Yellow Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Yellow Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Yellow Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Yellow Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Yellow Fever (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Yellow Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Yellow Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arno Therapeutics Inc
  • Bavarian Nordic A/S
  • Ennaid Therapeutics LLC
  • Fab'entech SA
  • iBio Inc
  • Johnson & Johnson
  • MORE
Introduction

Yellow Fever - Overview

Yellow Fever - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Yellow Fever - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Yellow Fever - Companies Involved in Therapeutics Development

Arno Therapeutics Inc

Bavarian Nordic A/S

BioCryst Pharmaceuticals Inc

Ennaid Therapeutics LLC

Fab'entech SA

iBio Inc

Johnson & Johnson

Sihuan Pharmaceutical Holdings Group Ltd

Valneva SE

Yellow Fever - Drug Profiles

AR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FDX-000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galidesivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JK-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Yellow Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XRX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever [strain YF17D] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

yellow fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Yellow Fever - Dormant Projects

Yellow Fever - Product Development Milestones

Featured News & Press Releases

Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine

Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial

Apr 07, 2011: Xcellerex Announces Positive Results From Phase I Clinical Trial Of XRX-001

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Yellow Fever, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Yellow Fever - Pipeline by Arno Therapeutics Inc, H2

Yellow Fever - Pipeline by Bavarian Nordic A/S, H2

Yellow Fever - Pipeline by BioCryst Pharmaceuticals Inc, H2

Yellow Fever - Pipeline by Ennaid Therapeutics LLC, H2

Yellow Fever - Pipeline by Fab'entech SA, H2

Yellow Fever - Pipeline by iBio Inc, H2

Yellow Fever - Pipeline by Johnson & Johnson, H2

Yellow Fever - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H2

Yellow Fever - Pipeline by Valneva SE, H2

Yellow Fever - Dormant Projects, H2

List of Figures

Number of Products under Development for Yellow Fever, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Arno Therapeutics Inc
  • Bavarian Nordic A/S
  • BioCryst Pharmaceuticals Inc
  • Ennaid Therapeutics LLC
  • Fab'entech SA
  • iBio Inc
  • Johnson & Johnson
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Valneva SE
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll